---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-014613"
form_type: "8-K"
ticker: "AQST"
cik: "0001398733"
company_name: "Aquestive Therapeutics, Inc."
filed_at: "2024-03-21T23:59:59+00:00"
generated_at: "2026-06-04T09:44:20.180947+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Aquestive Therapeutics prices $75M public offering of 16.7M shares at $4.50 per share

## Summary
- Offering of 16,666,667 shares at $4.50 per share; gross proceeds ~$75M, net ~$69.8M.
- Underwriters granted 30-day option to purchase up to 2,500,000 additional shares.
- Proceeds to advance Anaphylm (epinephrine) sublingual film and Libervant (diazepam) buccal film.
- Closing expected on or about March 22, 2024; Leerink Partners and Piper Sandler lead.
- Company expects net proceeds plus existing cash to fund operations through December 2025.

## SEC filing metadata
- accession: 0001140361-24-014613
- form_type: 8-K
- ticker: AQST
- cik: 0001398733
- company_name: Aquestive Therapeutics, Inc.
- filed_at: 2024-03-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1398733/000114036124014613/0001140361-24-014613-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1398733/000114036124014613/ny20024600x3_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-014613
- JSON: https://secwatch.observer/filing/0001140361-24-014613.json
- Plain text: https://secwatch.observer/filing/0001140361-24-014613.txt

## Key facts
- Material Agreements
  Aquestive Therapeutics, Inc. entered into Underwriting Agreement with Leerink Partners LLC and Piper Sandler & Co. valued at $69.8 million net proceeds (effective 2024-03-19).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Leerink Partners LLC and Piper Sandler & Co.
  - Value: $69.8 million net proceeds
  - Effective: 2024-03-19
  source text: On March 19, 2024, Aquestive Therapeutics, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") by and among the Company and Leerink Partners LLC and Piper Sandler & Co., as representatives of the several underwriters named therein (the "Underwriters"), relating to an underwritten public offering of 16,666,667 shares of the Company's common stock, par value $0.001 per share ("Common Stock"), at a public offering price of $4.50 per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1398733/000114036124014613/0001140361-24-014613-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.